Exploring the Mechanism of Action of Omega-3 Fatty Acids and the Potential Impact on CVD Risk Reduct...
Download
1 / 26

Panelists - PowerPoint PPT Presentation


  • 154 Views
  • Uploaded on

Exploring the Mechanism of Action of Omega-3 Fatty Acids and the Potential Impact on CVD Risk Reduction. Panelists. Goals.  -3 Fatty Acids. Why the Interest in Marine-Derived  -3 Fatty Acids?. Cardioprotective Effects of  -3 Fatty Acids.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Panelists' - dusan


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Exploring the Mechanism of Action of Omega-3 Fatty Acids and the Potential Impact on CVD Risk Reduction


Panelists
Panelists the Potential Impact on CVD Risk Reduction


Goals
Goals the Potential Impact on CVD Risk Reduction


3 fatty acids
the Potential Impact on CVD Risk Reduction-3 Fatty Acids


Why the interest in marine derived 3 fatty acids
Why the Interest in Marine-Derived the Potential Impact on CVD Risk Reduction-3 Fatty Acids?


Cardioprotective effects of 3 fatty acids
Cardioprotective Effects of the Potential Impact on CVD Risk Reduction-3 Fatty Acids


Possible mechanism of action for tg lowering effects of 3 fatty acids
Possible Mechanism of Action for TG-Lowering Effects of the Potential Impact on CVD Risk Reduction-3 Fatty Acids


Select 3 outcomes studies
Select the Potential Impact on CVD Risk Reduction-3 Outcomes Studies


3 ethyl esters and lipid levels in patients with tg levels 500 mg dl
the Potential Impact on CVD Risk Reduction-3 Ethyl Esters and Lipid Levels in Patients With TG Levels > 500 mg/dL


Statin 3 combos primary and secondary efficacy results
Statin + the Potential Impact on CVD Risk Reductionω-3: COMBOS Primary and Secondary Efficacy Results


Icosapent ethyl pure epa median placebo adjusted change from baseline for efficacy end points
Icosapent Ethyl (Pure EPA): Median Placebo-Adjusted Change From Baseline for Efficacy End Points


Anchor trial
ANCHOR Trial From Baseline for Efficacy End Points


Anchor trial results cont
ANCHOR Trial Results (cont) From Baseline for Efficacy End Points


Atp iii treatment recommendations for elevated tg levels
ATP III Treatment Recommendations for Elevated TG Levels From Baseline for Efficacy End Points


Effects of nutrition practices on tg level lowering
Effects of Nutrition Practices From Baseline for Efficacy End Pointson TG Level Lowering


Clinical outcome studies evaluating high tg level subgroups
Clinical Outcome Studies Evaluating From Baseline for Efficacy End PointsHigh TG Level Subgroups


Pharmacologic therapy for very high tg levels
Pharmacologic Therapy for Very High TG Levels From Baseline for Efficacy End Points


Pharmacologic therapy for very high tg levels1
Pharmacologic Therapy for Very High TG Levels From Baseline for Efficacy End Points


Abbreviations
Abbreviations From Baseline for Efficacy End Points


Abbreviations cont
Abbreviations (cont) From Baseline for Efficacy End Points


Abbreviations cont1
Abbreviations (cont) From Baseline for Efficacy End Points


References
References From Baseline for Efficacy End Points


References cont
References (cont) From Baseline for Efficacy End Points


References cont1
References (cont) From Baseline for Efficacy End Points


References cont2
References (cont) From Baseline for Efficacy End Points


ad